Difference between revisions of "Periampullary adenocarcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence !Comparator !Efficacy |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy |-") |
||
| Line 37: | Line 37: | ||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| − | !Study | + | !style="width: 25%"|Study |
| − | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| − | !Comparator | + | !style="width: 25%"|Comparator |
| − | ![[Levels_of_Evidence#Efficacy|Efficacy]] | + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] |
|- | |- | ||
|[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | |[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | ||
Revision as of 03:03, 19 August 2018
| Section editor | Page editor | ||
|---|---|---|---|
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
 |
Ivy Abraham, MD Chicago, IL |
0 regimens on this page
0 variants on this page
|
Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.
Guidelines
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Adjuvant therapy
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Neoptolemos et al. 2012 (ESPAC-3) | Phase III (C) | 5-FU & Leucovorin Gemcitabine |
Seems not superior |
Preceding treatment
- Surgery
References
- Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed